{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-316929","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2026-07-27T12:05:07+00:00","discovered_at":"2026-07-27T12:10:00.396111+00:00","generated_at":"2026-07-27T12:10:18.770650+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"CytomX appoints Charles Fuchs to Board of Directors as Class II director","bullets":["Dr. Fuchs appointed effective July 24, 2026, as Class II director with term expiring at 2029 annual meeting.","Receives option to purchase 118,000 shares at closing price on appointment date, vesting monthly over 3 years.","Will receive standard non-employee director compensation and enter into indemnification agreement.","No material transactions or arrangements between Dr. Fuchs and the Company exceeding $120,000."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-316929","json":"https://secwatch.observer/filing/0001193125-26-316929.json","markdown":"https://secwatch.observer/filing/0001193125-26-316929.md","text":"https://secwatch.observer/filing/0001193125-26-316929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526316929/0001193125-26-316929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526316929/d30807d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T12:10:18.770650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"598afcf230","claim":"Charles Fuchs was appointed as Director at CytomX Therapeutics, Inc..","evidence_excerpt":"On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective immediately, as a Class II director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526316929/0001193125-26-316929-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}